Didyou know this drug is produced in CHO cells?
Evkeeza from Regeneron was approved by the FDA in 2021 as an add-on treatment for patients aged 12 years and older with homozygous familial #hypercholesterolemia, a genetic condition that causes severely high cholesterol. Its activeingredient is evinacumab-dgnb, a monoclonalantibody produced in CHO cells acting as an angiopoietin-like 3 inhibitor. Are you involved in R&D on monoclonal antibodies? We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through […]